Back to Archived News
Imaging3 Receives Notice of Allowance for Its Continuation Patent
Wednesday, September 12, 2007
Patent Number 6,754,297 Is Added to Imaging3's Intellectual Property
Burbank, CA -- Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today announces that the company has received Notice of Allowance of the Company's Continuation in Part patent application.
"This is exceptional news and provides further coverage and strength to our existing patent as well as adding value to the Company's intellectual property portfolio," stated Dean Janes, Chairman and CEO of Imaging3. "All of our 27 claims were allowed in this continuation in part application, which further confirms our initial extensive research into this intellectual property performed by Imaging3 and our patent law firm, Pillsbury, Winthrop, Shaw, Pittman, LLC," stated Mr. Janes.
About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at www.imaging3.com.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
Back to Archived News
